{
    "clinical_study": {
        "@rank": "23386", 
        "arm_group": [
            {
                "arm_group_label": "DR group", 
                "arm_group_type": "Experimental", 
                "description": "In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex\u00ae, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started."
            }, 
            {
                "arm_group_label": "PR group", 
                "arm_group_type": "Active Comparator", 
                "description": "In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol\u00ae, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan)."
            }
        ], 
        "brief_summary": {
            "textblock": "Adequate, safe sedation is essential for Endoscopic submucosal dissection. Dexmedetomidine\n      is a potent and selective a2-adrenoceptor agonist used for sedative and analgesic effects,\n      but it is limited to use alone. The investigators designed this study to compare the effect\n      and safety of two sedatives, dexmedetomidine and propofol in Endoscopic Submucosal\n      Dissection (ESD), when sufficient analgesia-remifentanil is administered all throughout the\n      procedure."
        }, 
        "brief_title": "A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Early Gastric Cancer Patients Who Were Scheduled for Endoscopic Submucosal Dissection", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226520\n\n          -  American Society of Anaesthesiologists(ASA) physical status classification I~III\n\n          -  Early gastric cancer patients who were scheduled for Endoscopic submucosal dissection\n\n        Exclusion Criteria:\n\n          -  Age < 20\n\n          -  American Society of Anaesthesiologists(ASA) physical status classification IV\n\n          -  those with end-organ diseases (i.e. heart failure, respiratory failure, hepatic\n             failure, renal failure)\n\n          -  known drug allergies or history of drug abuse\n\n          -  psychological disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920113", 
            "org_study_id": "4-2012-0621"
        }, 
        "intervention": [
            {
                "arm_group_label": "DR group", 
                "intervention_name": "Dexmedetomidine - remifentanil group", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PR group", 
                "intervention_name": "Propofol - remifentanil group", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Propofol", 
                "Remifentanil", 
                "Dexmedetomidine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endoscopic submucosal dissection", 
            "propofol", 
            "remifentanil", 
            "dexmedetomidine", 
            "efficacy", 
            "safeness"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Anesthesiology & Pain Medicine, Yonsei university college of medicine"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "other_outcome": [
            {
                "description": "Patients' satisfaction : investigate in four steps questionaire (very good, good, bearable and unbearable) when the patients' were discharged from PACU", 
                "measure": "A comparison of patient's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil", 
                "safety_issue": "No", 
                "time_frame": "within 24hrs after procedure"
            }, 
            {
                "description": "Subjects' motility grading during procedure, easiness of procedure, operator's satisfaction : investigate in four steps questionaires by the operator after the procedure", 
                "measure": "A comparison of gastric motility, easiness for procedure, operator's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil", 
                "safety_issue": "No", 
                "time_frame": "right after the drugs had administered"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety : whether the complications as follows occur or not\nsystolic blood pressure under 90mmHg or 20% out of range of the baseline SBP\nheart rate under 50bpm\noxygen saturation under 90%, respiratory rate under 7 per minute", 
            "measure": "A comparison of safety during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil", 
            "safety_issue": "No", 
            "time_frame": "right after the drugs had administered"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy :\nwhether a bolus injection of 10 mg of propofol was administered or not\nevaluating the depth of sedation using MOAA/S scale all through the procedure\nwhether the en bloc resection, complete resection were done or not under the sedation", 
            "measure": "A comparison of efficacy during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil", 
            "safety_issue": "No", 
            "time_frame": "right after the drugs had administered"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}